Assaf M.

CEO of Voyant Bio | Rewiring immune cell interactions to outsmart cancer | Merck Digital Sciences Studio | 5050 @ 50 Years | Immuno-oncology | Computational genomics | Spatial biology | AI/ML

📍 United States🔄 Updated October 2026💼 1 investments📅 2 years investing🗓 Last invested Aug 2024
VC🌍 United States
1
Total investments
0
Early stage
0
Mid stage
0
Late stage
2y
Years active

Portfolio

0 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
No investments found
Experience · 2 entries
All (2)
Investments (1)
Founder (1)
2024
Angel Investor
Aug 2024
Founded in San Diego, CA, NuFund is one of the largest, most active and most successful early-stage investor groups over the past 20+ years. We represent diverse backgrounds and perspectives, and work together to foster a culture of excellence, respect, innovation, and fun.
Founder & CEO
Jul 2024
Cancer immunotherapy fails in 80% of patients due to break down in immune cell interactions. Voyant Bio has developed a spatial biology platform to enhance immunity against multiple cancers by rewiring immune cell interactions. Voyant’s platform has the potential to radically improve treatment efficacy for over a third of the patients who fail to respond to current cancer immunotherapies, representing an $100B+ opportunity.